Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Mol Neurodegener ; 15(1): 64, 2020 11 04.
Article in English | MEDLINE | ID: mdl-33148293

ABSTRACT

BACKGROUND: The spread of tau pathology in Alzheimer's disease (AD) is mediated by cell-to-cell transmission of pathological tau seeds released from neurons that, upon internalization by recipient neurons, template the misfolding of naïve cellular tau, thereby propagating fibrillization. We hypothesize that anti-tau monoclonal antibodies (mAbs) that selectively bind to pathological tau seeds will inhibit propagation of tau aggregates and reduce the spread of tau pathology in vivo. METHODS: We inoculated mice with human AD brain-derived extracts containing tau paired helical filaments (AD-tau) and identified two novel mAbs, DMR7 and SKT82, that selectively bind to a misfolded pathological conformation of tau relative to recombinant tau monomer. To evaluate the effects of these mAbs on the spread of pathological tau in vivo, 5xFAD mice harboring significant brain Aß plaque burden were unilaterally injected with AD-tau in the hippocampus, to initiate the formation of neuritic plaque (NP) tau pathology, and were treated weekly with intraperitoneal (i.p.) injections of DMR7, SKT82, or IgG isotype control mAbs. RESULTS: DMR7 and SKT82 bind epitopes comprised of the proline-rich domain and c-terminal region of tau and binding is reduced upon disruption of the pathological conformation of AD-tau by chemical and thermal denaturation. We found that both DMR7 and SKT82 immunoprecipitate pathological tau and significantly reduce the seeding of cellular tau aggregates induced by AD-tau in primary neurons by 60.5 + 13.8% and 82.2 + 8.3%, respectively, compared to IgG control. To investigate the mechanism of mAb inhibition, we generated pH-sensitive fluorophore-labeled recombinant tau fibrils seeded by AD-tau to track internalization of tau seeds and demonstrate that the conformation-selective tau mAbs inhibit the internalization of tau seeds. DMR7 and SKT82 treatment reduced hyperphosphorylated NP tau as measured with AT8 immunohistochemistry (IHC) staining, but did not achieve statistical significance in the contralateral cortex and SKT82 significantly reduced tau pathology in the ipsilateral hippocampus by 24.2%; p = 0.044. CONCLUSIONS: These findings demonstrate that conformation-selective tau mAbs, DMR7 and SKT82, inhibit tau pathology in primary neurons by preventing the uptake of tau seeds and reduce tau pathology in vivo, providing potential novel therapeutic candidates for the treatment of AD.


Subject(s)
Alzheimer Disease/pathology , Antibodies, Monoclonal/pharmacology , Neurons/pathology , tau Proteins/antagonists & inhibitors , Animals , Disease Models, Animal , Humans , Mice , Neurons/drug effects , tau Proteins/drug effects
2.
Methods Mol Biol ; 1948: 45-57, 2019.
Article in English | MEDLINE | ID: mdl-30771169

ABSTRACT

The accumulation of intraneuronal inclusions containing misfolded alpha-synuclein (aSyn) within the central nervous system (CNS) is a common feature found in several neurodegenerative disorders including Parkinson's disease (PD). Emerging evidence indicates that aSyn amyloid fibrils, a configuration that is present within these characteristic inclusions, are capable of self-replicating by templating the conversion of endogenously expressed aSyn in neurons. Stereotaxic administration of synthetic α-synuclein preformed fibrils (PFFs) into the mouse brain has been shown to seed the formation of intracellular aSyn pathology reminiscent of Lewy body (LB) inclusions present in human PD and related synucleinopathies. Moreover, pathology can be targeted to specific CNS regions. This experimental approach provides a versatile platform for investigating PD-like LB pathology in vivo. We focus here on procedures for initiating aSyn inclusion formation at various regions of the mouse brain using computer-assisted motorized stereotaxic microinjection of aSyn PFFs and discuss appropriate strategies for controls and analysis.


Subject(s)
Amyloid/metabolism , Brain/metabolism , Brain/pathology , Stereotaxic Techniques , alpha-Synuclein/metabolism , Animals , Biomarkers , Immunohistochemistry/methods , Inclusion Bodies/metabolism , Mice , Neurons/metabolism , Neurons/pathology , Protein Aggregates , Protein Aggregation, Pathological
3.
J Neuropathol Exp Neurol ; 77(3): 216-228, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29415231

ABSTRACT

Aggregation of tau into fibrillar structures within the CNS is a pathological hallmark of a clinically heterogeneous set of neurodegenerative diseases termed tauopathies. Unique misfolded conformations of tau, referred to as strains, are hypothesized to underlie the distinct neuroanatomical and cellular distribution of pathological tau aggregates. Here, we report the identification of novel tau monoclonal antibodies (mAbs) that selectively bind to an Alzheimer disease (AD)-specific conformation of pathological tau. Immunohistochemical analysis of tissue from various AD and nonAD tauopathies demonstrate selective binding of mAbs GT-7 and GT-38 to AD tau pathologies and absence of immunoreactivity for tau aggregates that are diagnostic of corticobasal degenerations (CBD), progressive supranuclear palsy (PSP), and Pick's disease (PiD). In cases with co-occurring AD tauopathy, GT-7 and GT-38 distinguish comorbid AD tau from pathological tau in frontotemporal lobar degeneration characterized by tau inclusions (FTLD-Tau), as confirmed by the presence of both 3 versus 4 microtubule-binding repeat isoforms (3R and 4R tau isoforms, respectively), in AD neurofibrillary tangles but not in the tau aggregates of CBD, PSP, or PiD. These findings support the concept of an AD-specific tau strain. The mAbs described here enable the selective detection of AD tau pathology in nonAD tauopathies.


Subject(s)
Alzheimer Disease/diagnosis , Antibodies, Monoclonal/metabolism , Molecular Conformation , Tauopathies/metabolism , tau Proteins/immunology , tau Proteins/metabolism , Adult , Aged , Aged, 80 and over , Alzheimer Disease/metabolism , Antibodies, Monoclonal/chemistry , Female , Humans , Immunohistochemistry , Male , Middle Aged , Neurofibrillary Tangles/metabolism , Neurofibrillary Tangles/pathology , Phosphorylation , Pick Disease of the Brain/metabolism , Pick Disease of the Brain/pathology , Protein Conformation , Protein Isoforms/metabolism , Supranuclear Palsy, Progressive/metabolism , Supranuclear Palsy, Progressive/pathology , Tauopathies/pathology
4.
J Neurosci ; 37(47): 11485-11494, 2017 11 22.
Article in English | MEDLINE | ID: mdl-28986461

ABSTRACT

Neurodegenerative proteinopathies characterized by intracellular aggregates of tau proteins, termed tauopathies, include Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) with tau pathology (FTLD-tau), and related disorders. Pathological tau proteins derived from human AD brains (AD-tau) act as proteopathic seeds that initiate the templated aggregation of soluble tau upon intracerebral injection into tau transgenic (Tg) and wild-type mice, thereby modeling human tau pathology. In this study, we found that aged Tg mice of both sexes expressing human tau proteins harboring a pathogenic P301L MAPT mutation labeled with green fluorescent protein (T40PL-GFP Tg mouse line) exhibited hyperphosphorylated tau mislocalized to the somatodentritic domain of neurons, but these mice did not develop de novo insoluble tau aggregates, which are characteristic of human AD and related tauopathies. However, intracerebral injections of either T40PL preformed fibrils (PFFs) or AD-tau seeds into T40PL-GFP mice induced abundant intraneuronal pathological inclusions of hyperphosphorylated T40PL-GFP. These injections of pathological tau resulted in the propagation of tau pathology from the injection site to neuroanatomically connected brain regions, and these tau inclusions consisted of both T40PL-GFP and WT endogenous mouse tau. Primary neurons cultured from the brains of neonatal T40PL-GFP mice provided an informative in vitro model for examining the uptake and localization of tau PFFs. These findings demonstrate the seeded aggregation of T40PL-GFP in vivo by synthetic PFFs and human AD-tau and the utility of this system to study the neuropathological spread of tau aggregates.SIGNIFICANCE STATEMENT The stereotypical spread of pathological tau protein aggregates have recently been attributed to the transmission of proteopathic seeds. Despite the extensive use of transgenic mouse models to investigate the propagation of tau pathology in vivo, details of the aggregation process such as the early seeding events leading to new tau pathology have remained elusive. This study validates the use of GFP-labeled tau expressed by neurons in vivo and in vitro as models for investigating mechanisms underlying the seeded transmission of tau pathology as well as tau-focused drug discovery to identify disease-modifying therapies for AD and related tauopathies.


Subject(s)
Alzheimer Disease/metabolism , tau Proteins/toxicity , Alzheimer Disease/etiology , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Disease Models, Animal , Female , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Injections, Intraventricular , Male , Mice , Mutation , Neurons/metabolism , Neurons/pathology , Recombinant Proteins , tau Proteins/administration & dosage , tau Proteins/genetics , tau Proteins/metabolism
5.
J Alzheimers Dis ; 31(2): 439-45, 2012.
Article in English | MEDLINE | ID: mdl-22571982

ABSTRACT

The best-studied biomarkers of Alzheimer's disease (AD) are the pathologically-linked cerebrospinal fluid (CSF) proteins amyloid-ß 42 (Aß(1-42)), total tau (t-tau), and tau phosphorylated on amino acid 181 (p-tau(181)). Many laboratories measure these proteins using enzyme-linked immunosorbent assay (ELISA). Multiplex xMAP Luminex is a semi-automated assay platform with reduced intra-sample variance, which could facilitate its use in CLIA-approved clinical laboratories. CSF concentrations of these three biomarkers reported using xMAP technology differ from those measured by the most commonly used ELISA, confounding attempts to compare results. To develop a model for converting between xMAP and ELISA levels of the three biomarkers, we analyzed CSF samples from 140 subjects (59 AD, 30 controls, 34 with mild cognitive impairment, and 17 with Parkinson's disease, including 1 with dementia). Log-transformation of ELISA and xMAP levels made the variance constant in all three biomarkers and improved the linear regression: t-tau concentrations were highly correlated (r = 0.94); p-tau(181) concentrations by ELISA can be better predicted using both the t-tau and p-tau(181) xMAP values (r = 0.96) as compared to p-tau(181) concentrations alone (r = 0.82); correlation of Aß(1-42) concentrations was relatively weaker but still high (r = 0.77). Among all six protein/assay combinations, xMAP Aß(1-42) had the best accuracy for diagnostic classification (88%) between AD and control subjects. In conclusion, our study demonstrates that multiplex xMAP is an appropriate assay platform providing results that can be correlated with research-based ELISA values, facilitating the incorporation of this diagnostic biomarker into routine clinical practice.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , Reagent Kits, Diagnostic/standards , Aged , Aged, 80 and over , Amyloid beta-Peptides/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Enzyme-Linked Immunosorbent Assay/methods , Enzyme-Linked Immunosorbent Assay/standards , Female , Humans , Longitudinal Studies , Male , Middle Aged , Peptide Fragments/cerebrospinal fluid , tau Proteins/cerebrospinal fluid
6.
J Neurosci ; 31(21): 7691-9, 2011 May 25.
Article in English | MEDLINE | ID: mdl-21613482

ABSTRACT

Alzheimer's disease (AD) is characterized by the accumulation of intraneuronal tau and extracellular amyloid-ß (Aß) peptide. A triple transgenic (Tg) mouse (3xTg-AD) was reported to develop Aß plaques and tau inclusions as well as remarkable accumulations of intracellular Aß that were suggested to be the initiators of AD pathogenesis. However, it was unclear whether the anti-Aß antibodies were able to distinguish Aß peptide from the same Aß epitopes within the amyloid precursor protein (APP). To further elucidate the identity of the immunoreactive intraneuronal material in 3xTg-AD mice, we conducted immunohistochemical, biochemical, and ultrastructural studies using a well characterized panel of antibodies that distinguish Aß within APP from cleaved Aß peptides. We found that the intraneuronal material shared epitopes with full-length APP but not free Aß. To demonstrate unequivocally that this intraneuronal material was not free Aß peptide, we generated 3xTg-AD mice deficient for ß-secretase (BACE), the protease required for Aß generation from APP. In the absence of Aß production, robust intraneuronal APP immunostaining was detected in the 3xTg-AD/BACE(-/-) mice. Finally, we found that the formation of tau lesions was not different between 3xTg-AD versus 3xTg-AD/BACE(-/-) mice, thereby demonstrating that tau pathology forms independently from Aß peptide generation in this mouse model. Although we cannot corroborate the presence of intraneuronal Aß peptide in 3xTg-AD mice, our findings warrant further study as to the role of aberrant APP accumulation in this unique model of AD.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/physiology , Amyloid beta-Protein Precursor/physiology , Disease Models, Animal , Nerve Degeneration/metabolism , Neurons/metabolism , tau Proteins/physiology , Alzheimer Disease/pathology , Animals , Mice , Mice, Transgenic , Nerve Degeneration/pathology , Neurons/pathology
7.
J Neurosci ; 28(30): 7687-98, 2008 Jul 23.
Article in English | MEDLINE | ID: mdl-18650345

ABSTRACT

alpha-Synuclein (SYN) is the major component of Lewy bodies, the neuropathological hallmarks of Parkinson's disease (PD). Missense mutations and multiplications of the SYN gene cause autosomal dominant inherited PD. Thus, SYN is implicated in the pathogenesis of PD. However, the mechanism whereby SYN promotes neurodegeneration remains unclear. Familial PD with SYN gene mutations are rare because the majority of PD is sporadic and emerging evidence indicates that sporadic PD may result from genetic and environmental risk factors including neuroinflammation. Hence, we examined the relationship between SYN dysfunction and neuroinflammation in mediating dopaminergic neurodegeneration in mice and dopaminergic neuronal cultures derived from wild-type SYN and mutant A53T SYN transgenic mice in a murine SYN-null (SYNKO) background (M7KO and M83KO, respectively). Stereotaxic injection of an inflammagen, lipopolysaccharide, into substantia nigra of these SYN genetically engineered mice induced similar inflammatory reactions. In M7KO and M83KO, but not in SYNKO mice, the neuroinflammation was associated with dopaminergic neuronal death and the accumulation of insoluble aggregated SYN as cytoplasmic inclusions in nigral neurons. Nitrated/oxidized SYN was detected in these inclusions and abatement of microglia-derived nitric oxide and superoxide provided significant neuroprotection in neuron-glia cultures from M7KO mice. These data suggest that nitric oxide and superoxide released by activated microglia may be mediators that link inflammation and abnormal SYN in mechanisms of PD neurodegeneration. This study advances understanding of the role of neuroinflammation and abnormal SYN in the pathogenesis of PD and opens new avenues for the discovery of more effective therapies for PD.


Subject(s)
Dopamine/metabolism , Neurodegenerative Diseases/complications , Neurodegenerative Diseases/genetics , Nitric Oxide Synthase/metabolism , Oxidative Stress/physiology , alpha-Synuclein/genetics , Analysis of Variance , Animals , Cell Count , Cells, Cultured , Coculture Techniques/methods , Embryo, Mammalian , Humans , Inflammation/chemically induced , Inflammation/genetics , Inflammation/metabolism , Inflammation/pathology , Lipopolysaccharides/adverse effects , Mice , Mice, Inbred C57BL , Mice, Transgenic , Mutation, Missense , Nerve Tissue Proteins/metabolism , Neuroglia/drug effects , Neuroglia/metabolism , Neurons/drug effects , Neurons/pathology , Neurons/physiology , Neurons/ultrastructure , alpha-Synuclein/deficiency
8.
J Neurosci ; 28(18): 4785-94, 2008 Apr 30.
Article in English | MEDLINE | ID: mdl-18448655

ABSTRACT

Alzheimer's disease (AD) amyloid plaques are composed of amyloid-beta (Abeta) peptides produced from proteolytic cleavage of amyloid precursor protein (APP). Isoprostanes, markers of in vivo oxidative stress, are elevated in AD patients and in the Tg2576 mouse model of AD-like Abeta brain pathology. To determine whether isoprostanes increase Abeta production, we delivered isoprostane iPF(2alpha)-III into the brains of Tg2576 mice. Although treated mice showed increased brain Abeta levels and plaque-like deposits, this was blocked by a thromboxane (TP) receptor antagonist, suggesting that TP receptor activation mediates the effects of iPF(2alpha)-III on Abeta. This hypothesis was supported by cell culture studies that showed that TP receptor activation increased Abeta and secreted APP ectodomains. This increase was a result of increased APP mRNA stability leading to elevated APP mRNA and protein levels. The increased APP provides more substrate for alpha and beta secretase proteolytic cleavages, thereby increasing Abeta generation and amyloid plaque deposition. To test the effectiveness of targeting the TP receptor for AD therapy, Tg2576 mice underwent long-term treatment with S18886, an orally available TP receptor antagonist. S18886 treatment reduced amyloid plaques, insoluble Abeta, and APP levels, thereby implicating TP receptor signaling as a novel target for AD therapy.


Subject(s)
Amyloid beta-Peptides/metabolism , Brain/drug effects , Brain/metabolism , Isoprostanes/pharmacology , Receptors, Thromboxane/physiology , Amyloid beta-Peptides/genetics , Amyloid beta-Protein Precursor/genetics , Animals , Brain/pathology , Cells, Cultured , Embryo, Mammalian , Enzyme Activation/drug effects , Enzyme-Linked Immunosorbent Assay/methods , Female , Gene Expression Regulation/drug effects , Humans , Immunoprecipitation/methods , Isoprostanes/metabolism , Mice , Mice, Transgenic , Naphthalenes/pharmacology , Neurons/drug effects , Neurons/metabolism , Peptide Fragments/metabolism , Propionates/pharmacology , Radioimmunoassay/methods , Receptors, Thromboxane/antagonists & inhibitors
9.
FEBS Lett ; 582(3): 427-33, 2008 Feb 06.
Article in English | MEDLINE | ID: mdl-18201567

ABSTRACT

The gamma-secretase complex, composed by presenilin, nicastrin, APH-1 and PEN-2, is involved in intramembranous proteolysis of membrane proteins, such as amyloid precursor protein or Notch. Cleavage occurs in multiple cellular compartments. Here, nicastrin mutants containing targeting signals to the endoplasmic reticulum, trans-Golgi network, lysosomes, or plasma membrane have been shown to yield active gamma-secretase complexes with different activities and specificities: wild-type and plasma membrane nicastrin complexes yielded the highest amounts of secreted amyloid-beta peptide (Abeta), predominantly Abeta40, whereas intracellular targeted mutants produced intracellular Abeta, with a comparatively higher amount of Abeta42. These results suggest that compartmental microenvironments play a role in gamma-secretase activity and specificity.


Subject(s)
Amyloid Precursor Protein Secretases/metabolism , Amyloid Precursor Protein Secretases/physiology , Amyloid beta-Peptides/biosynthesis , Membrane Glycoproteins/metabolism , Membrane Glycoproteins/physiology , Amino Acid Sequence , Animals , Cells, Cultured , Enzyme Activation , HeLa Cells , Humans , Mice , Molecular Sequence Data , Multiprotein Complexes/metabolism , Mutant Proteins/metabolism , Substrate Specificity , Tissue Distribution/physiology
10.
J Neurosci ; 27(26): 7006-10, 2007 Jun 27.
Article in English | MEDLINE | ID: mdl-17596449

ABSTRACT

A cardinal pathological lesion of Alzheimer's disease (AD) is the deposition of amyloid beta (Abeta) in the brain. We previously reported that exposing transgenic mice harboring APPswe/PS1deltaE9 transgenes to an enriched environment resulted in reduced levels of Abeta peptides and deposition, findings that were correlated with an increase in the expression of TTR, encoding transthyretin (TTR). TTR is expressed at high levels in the choroid plexus and known to bind Abeta peptides and modulate their aggregation in vitro and in vivo. To explore the impact of TTR expression on Abeta levels and deposition in vivo, we crossed ceAPPswe/PS1deltaE9 transgenic mice to mice with genetic ablations of TTR. We now report that the levels of detergent-soluble and formic acid-soluble levels of Abeta and deposition are elevated in the brains of ceAPPswe/PS1deltaE9/TTR+/- mice compared with age-matched ceAPPswe/PS1deltaE9/TTR+/+ mice. Moreover, Abeta deposition is significantly accelerated in the hippocampus and cortex of ceAPPswe/PS1deltaE9/TTR+/- mice. Our results strongly suggest that TTR plays a critical role in modulating Abeta deposition in vivo.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Brain/metabolism , Prealbumin/genetics , Alzheimer Disease/physiopathology , Amyloid beta-Protein Precursor/genetics , Animals , Brain/pathology , Brain/physiopathology , Disease Models, Animal , Gene Deletion , Gene Expression Regulation/genetics , Mice , Mice, Knockout , Mice, Transgenic , Plaque, Amyloid/genetics , Plaque, Amyloid/metabolism , Presenilin-1/genetics , Up-Regulation/genetics
11.
Am J Pathol ; 170(2): 658-66, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17255333

ABSTRACT

The factors initiating or contributing to the pathogenesis of Parkinson's disease and related neurodegenerative synucleinopathies are still largely unclear, but environmental factors such as pesticides have been implicated. In this study, A53T mutant human alpha-synuclein transgenic mice (M83), which develop alpha-synuclein neuropathology, were treated with the pesticides paraquat and maneb (either singly or together), and their effects were analyzed. Immunohistochemical and biochemical analyses showed that chronic treatment of M83 transgenic mice with both pesticides (but not with either pesticide alone) drastically increased neuronal alpha-synuclein pathology throughout the central nervous system including the hippocampus, cerebellum, and sensory and auditory cortices. alpha-Synuclein-associated mitochondrial degeneration was observed in M83 but not in wild-type alpha-synuclein transgenic mice. Because alpha-synuclein inclusions accumulated in pesticide-exposed M83 transgenic mice without a motor phenotype, we conclude that alpha-synuclein aggregate formation precedes disease onset. These studies support the notion that environmental factors causing nitrative damage are closely linked to mechanisms underlying the formation of alpha-synuclein pathologies and the onset of Parkinson's-like neurodegeneration.


Subject(s)
Environmental Exposure/adverse effects , Fungicides, Industrial/toxicity , Maneb/toxicity , Paraquat/toxicity , Parkinson Disease/pathology , alpha-Synuclein , Animals , Brain/metabolism , Brain/ultrastructure , Drug Synergism , Humans , Inclusion Bodies/genetics , Inclusion Bodies/metabolism , Inclusion Bodies/pathology , Maneb/agonists , Mice , Mice, Transgenic , Mitochondria/metabolism , Mitochondria/ultrastructure , Mutation, Missense , Paraquat/agonists , Parkinson Disease/genetics , Parkinson Disease/metabolism , alpha-Synuclein/biosynthesis , alpha-Synuclein/genetics
13.
Am J Pathol ; 167(5): 1361-9, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16251420

ABSTRACT

Impaired rapid eye movement sleep (REMS) is commonly observed in Alzheimer's disease, suggesting injury to mesopontine cholinergic neurons. We sought to determine whether abnormal beta-amyloid peptides impair REMS and injure mesopontine cholinergic neurons in transgenic (hAPP695.SWE) mice (Tg2576) that model brain amyloid pathologies. Tg2576 mice and wild-type littermates were studied at 2, 6, and 12 months by using sleep recordings, contextual fear conditioning, and immunohistochemistry. At 2 months of age, REMS was indistinguishable by genotype but was reduced in Tg2576 mice at 6 and 12 months. Choline acetyltransferase-positive neurons in the pedunculopontine tegmentum of Tg2576 mice at 2 months evidenced activated caspase-3 immunoreactivity, and at 6 and 12 months the numbers of pedunculopontine tegmentum choline acetyltransferase-positive neurons were reduced in the Tg2576 mice. Other cholinergic groups involved in REMS were unperturbed. At 12 months, Tg2576 mice demonstrated increased 3-nitrotyrosine immunoreactivity in cholinergic projection sites but not in cholinergic soma. We have identified a population of selectively compromised cholinergic neurons in young Tg2576 mice that manifest early onset REMS impairment. The differential vulnerability of these cholinergic neurons to Abeta injury provides an invaluable tool with which to understand mechanisms of sleep/wake perturbations in Alzheimer's disease.


Subject(s)
Alzheimer Disease/complications , Cholinergic Fibers/pathology , Pedunculopontine Tegmental Nucleus/pathology , REM Sleep Behavior Disorder/etiology , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/analysis , Animals , Brain/pathology , Brain Chemistry , Caspase 3 , Caspases/analysis , Disease Models, Animal , Immunohistochemistry , Memory Disorders , Mice , Mice, Transgenic , REM Sleep Behavior Disorder/metabolism , REM Sleep Behavior Disorder/pathology , Tyrosine/analogs & derivatives , Tyrosine/analysis
14.
Ann Neurol ; 57(5): 721-9, 2005 May.
Article in English | MEDLINE | ID: mdl-15852395

ABSTRACT

We assessed cerebrospinal fluid (CSF) levels of tau and other biomarkers of neurodegenerative disease. CSF tau levels vary widely in reports of frontotemporal dementia (FTD). CSF samples were assayed for tau, amyloid beta1-42 (A1-42), and the isoprostane 8,12-iso-iPF2a-VI (iP) prospectively in 64 patients with FTD, retrospectively in 26 autopsied cases with FTD or Alzheimer's disease (AD), and in 13 healthy seniors. To validate our observations in vivo, we correlated CSF tau levels with cortical atrophy in 17 FTD patients using voxel-based morphometry analyses of high-resolution magnetic resonance imaging. CSF levels of tau, Abeta1-42, and iP differed significantly in FTD compared with AD. Individual patient analyses showed that 34% of FD patients had significantly low levels of CSF tau, although this was never seen in AD. A discriminant analysis based on CSF levels of tau, Abeta1-42, and iP was able to classify 88.5% of these patients in a manner that corresponds to their clinical or autopsy diagnosis. Magnetic resonance imaging studies showed that CSF tau levels correlate significantly with right frontal and left temporal cortical atrophy, brain regions known to be atrophic in patients with autopsy-proved FTD. We conclude that CSF tau levels are significantly reduced in many patients with FTD.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Dementia/cerebrospinal fluid , Frontal Lobe , Age of Onset , Aged , Alzheimer Disease/psychology , Amyloid beta-Peptides/cerebrospinal fluid , Atrophy , Biomarkers , Cerebral Cortex/pathology , Cohort Studies , Dementia/psychology , Female , Humans , Isoprostanes/cerebrospinal fluid , Magnetic Resonance Imaging , Male , Middle Aged , Neuropsychological Tests , Phenotype , Prospective Studies , ROC Curve , tau Proteins/cerebrospinal fluid
15.
Arch Neurol ; 60(12): 1696-702, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14676043

ABSTRACT

BACKGROUND: Tau and beta-amyloid (Abeta) are proposed diagnostic biomarkers for Alzheimer disease (AD). Previous studies report their relationship to clinical diagnoses of AD and other dementias. To understand their value as predictors of disease-specific pathology, levels determined during life must be correlated with definitive diagnoses in mixed dementia groups and cognitively normal subjects. OBJECTIVES: To correlate antemortem cerebrospinal fluid (CSF) tau and Abeta levels with definitive dementia diagnosis in a diverse group of patients; to calculate statistics for CSF tau and Abeta. DESIGN: Prospective study. SETTING: Ten clinics experienced in the diagnosis of neurodegenerative dementias. Patients One hundred six patients with dementia and 4 cognitively normal subjects with a definitive diagnosis, and 69 clinically diagnosed cognitively normal subjects. MAIN OUTCOME MEASURES: Correlation of CSF tau and Abeta with final diagnosis. RESULTS: Mean tau level was 612 pg/mL for the 74 patients with AD, 272 pg/mL for 10 patients with frontal dementia, 282 pg/mL for 3 patients with dementia with Lewy bodies, and 140 pg/mL for 73 cognitively normal control subjects. Tau was less than 334 pg/mL for 20 patients with AD. Abeta42 was reduced in patients with AD (61 fmol/mL) compared with patients with frontal dementia (133 fmol/mL) and control subjects (109 fmol/mL), but not compared with patients with dementia with Lewy bodies (14 fmol/mL) or prion disease (60 fmol/mL). CONCLUSIONS: Elevated CSF tau levels are associated with AD pathology and can help discriminate AD from other dementing disorders. However, some patients with AD have a level less than the mean +/- 2 SDs of the cognitively normal cohort.


Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Dementia/cerebrospinal fluid , Dementia/diagnosis , tau Proteins/cerebrospinal fluid , Adult , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Area Under Curve , Biomarkers/cerebrospinal fluid , Case-Control Studies , Cohort Studies , Humans , Lewy Body Disease/cerebrospinal fluid , Middle Aged , Prospective Studies , ROC Curve
16.
Public Health Nurs ; 20(6): 440-8, 2003.
Article in English | MEDLINE | ID: mdl-14629675

ABSTRACT

BACKGROUND: This article describes the application of the vulnerable populations conceptual model to rural health. Vulnerable populations are social groups who have an increased susceptibility to adverse health outcomes. Evidence of this differential in vulnerability or increased risk includes premature mortality, comparative morbidity, decreased functional status, and diminished quality of life. ORGANIZING FRAMEWORK: The vulnerable populations conceptual model postulates that there are interrelationships among resource availability, relative risk, and health status. Resource availability speaks to socioeconomic and environmental resources that are operationalized in this model as income, jobs, education, housing, availability of health care, quality of health care, and patterns of family and community life. Relative risk addresses the likelihood of exposure to risk factors and is reflected in lifestyle behaviors and choices and exposure to stressful events. Health status is operationalized as morbidity and mortality. FINDINGS: This review of the literature supports the utility of the vulnerable populations conceptual model in working with rural populations. IMPLICATIONS: This model has potential utility to inform nursing research, practice, and policy about the opportunities and resources needed to achieve and maintain health in rural communities.


Subject(s)
Community Health Planning/organization & administration , Models, Nursing , Rural Health , Vulnerable Populations , Health Services Accessibility/standards , Health Status , Health Status Indicators , Humans , Life Style , Needs Assessment , Primary Prevention , Risk , Risk Assessment , Socioeconomic Factors
17.
J Adv Nurs ; 37(1): 108-14, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11784404

ABSTRACT

AIM OF THE PAPER: This paper describes the use of story as a vehicle to inform aesthetic knowing in nursing. Because health care demands that nurses know two distinct languages, the language of nursing science with its quantifiable outcomes as well as the experiential observations of health and illness, it is critical that nurses be fluent in each discourse. BACKGROUND: Nursing scholars have long voiced a commitment to two epistemological domains: scientifically derived knowledge (empirics) as well as the expressive, creative, intuitive application of knowledge (aesthetics). In recognition of the need for these interpretive paradigms for practice, nursing scholars have sought to identify the kinds of knowing which provide the nursing discipline with its unique perspective. DISCUSSION: Stories mould every human encounter and telling one's story in the context of a trusting relationship allows women and nurses to journey together to uncover and discover the meanings inherent in the story. Through this mutual process of unfolding the story, nurses engage the women in deep reflection and focus on what 'might be' so that possibilities for the future are illuminated. This is important in all nursing, but particularly in women's health nursing because the emergence of story suggests that contextual, phenomena-centred knowledge has found its voice in the nursing care of women as a way of knowing that focuses on personal experience and relies on methods in which woman-to-woman caring facilitates the disclosure of the human health-illness experience. CONCLUSIONS: Storytelling is a useful strategy to inform aesthetic knowing in nursing. Stories supply a foundation for nursing scholarship because truly to hear women's stories require nurses analyse information, formulate hypotheses, and seek to understand the causal relationships as expressed by women. Through this analysis and attention to detail, nurses are able to glimpse possibilities for the future, thus transforming the experience.


Subject(s)
Interviews as Topic/methods , Nursing Research/methods , Women's Health , Communication , Empathy , Female , Humans , Philosophy, Nursing
18.
J Neurosci ; 22(2): 446-54, 2002 Jan 15.
Article in English | MEDLINE | ID: mdl-11784789

ABSTRACT

Traumatic brain injury (TBI) increases susceptibility to Alzheimer's disease (AD), but it is not known how TBI contributes to the onset or progression of this common late life dementia. To address this question, we studied neuropathological and behavioral consequences of single versus repetitive mild TBI (mTBI) in transgenic (Tg) mice (Tg2576) that express mutant human Abeta precursor protein, and we demonstrate elevated brain Abeta levels and increased Abeta deposition. Nine-month-old Tg2576 and wild-type mice were subjected to single (n = 15) or repetitive (n = 39) mTBI or sham treatment (n = 37). At 2 d and 9 and 16 weeks after treatment, we assessed brain Abeta deposits and levels in addition to brain and urine isoprostanes generated by lipid peroxidation in these mice. A subset of mice also was studied behaviorally at 16 weeks after injury. Repetitive but not single mTBI increased Abeta deposition as well as levels of Abeta and isoprostanes only in Tg mice, and repetitive mTBI alone induced cognitive impairments but no motor deficits in these mice. This is the first experimental evidence linking TBI to mechanisms of AD by showing that repetitive TBI accelerates brain Abeta accumulation and oxidative stress, which we suggest could work synergistically to promote the onset or drive the progression of AD. Additional insights into the role of TBI in mechanisms of AD pathobiology could lead to strategies for reducing the risk of AD associated with previous episodes of brain trauma and for preventing progressive brain amyloidosis in AD patients.


Subject(s)
Alzheimer Disease/physiopathology , Amyloidosis/physiopathology , Brain Injuries/physiopathology , Cognition Disorders/physiopathology , Disease Models, Animal , Alzheimer Disease/complications , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/biosynthesis , Amyloid beta-Protein Precursor/genetics , Amyloidosis/complications , Amyloidosis/pathology , Animals , Behavior, Animal , Biomarkers/analysis , Biomarkers/urine , Brain/pathology , Brain/physiopathology , Brain Injuries/complications , Brain Injuries/pathology , Cognition Disorders/complications , Cognition Disorders/pathology , Disease Progression , Disease Susceptibility/physiopathology , Female , Glial Fibrillary Acidic Protein/metabolism , Head Injuries, Closed/complications , Head Injuries, Closed/physiopathology , Humans , Isoprostanes/analysis , Isoprostanes/metabolism , Lipid Peroxidation , Male , Mice , Mice, Transgenic , Motor Activity , Neurologic Examination , Reaction Time
SELECTION OF CITATIONS
SEARCH DETAIL
...